The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVID
Open Access
- 10 May 2024
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (5) , 884-892.e4
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Inc
This publication has 8 references indexed in Scilit:
- Serotonin reduction in post-acute sequelae of viral infectionCell, 2023
- Distinguishing features of long COVID identified through immune profilingNature, 2023
- SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)Nature Immunology, 2023
- Long COVID: major findings, mechanisms and recommendationsNature Reviews Microbiology, 2023
- Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 SequelaeClinical Infectious Diseases, 2022
- Unexplained post-acute infection syndromesNature Medicine, 2022
- PROMIS®-29 v2.0 profile physical and mental health summary scoresQuality of Life Research, 2018
- Structure and mechanism of the complex between cytochrome P4503A4 and ritonavirProceedings of the National Academy of Sciences, 2010